[HTML][HTML] Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
RECOVERY Collaborative Group - Lancet (London, England), 2022 - ncbi.nlm.nih.gov
Background Aspirin has been proposed as a treatment for COVID-19 on the basis of its anti-
thrombotic properties. We aimed to evaluate the efficacy and safety of aspirin in patients
admitted to hospital with COVID-19. Methods In this randomised, controlled, open-label,
platform trial, several possible treatments were compared with usual care in patients
hospitalised with COVID-19. The trial took place at 177 hospitals in the UK, two hospitals in
Indonesia, and two hospitals in Nepal. Eligible and consenting adults were randomly …
thrombotic properties. We aimed to evaluate the efficacy and safety of aspirin in patients
admitted to hospital with COVID-19. Methods In this randomised, controlled, open-label,
platform trial, several possible treatments were compared with usual care in patients
hospitalised with COVID-19. The trial took place at 177 hospitals in the UK, two hospitals in
Indonesia, and two hospitals in Nepal. Eligible and consenting adults were randomly …
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
RECOVERY Collaborative Group, PW Horby… - Medrxiv, 2021 - medrxiv.org
Background REGEN-COV is a combination of 2 monoclonal antibodies (casirivimab and
imdevimab) that bind to two different sites on the receptor binding domain of the SARS-CoV-
2 spike protein. We aimed to evaluate the efficacy and safety of REGEN-COV in patients
admitted to hospital with COVID-19. Methods In this randomised, controlled, open-label
platform trial, several possible treatments were compared with usual care in patients
hospitalised with COVID-19. Eligible and consenting patients were randomly allocated (1: 1) …
imdevimab) that bind to two different sites on the receptor binding domain of the SARS-CoV-
2 spike protein. We aimed to evaluate the efficacy and safety of REGEN-COV in patients
admitted to hospital with COVID-19. Methods In this randomised, controlled, open-label
platform trial, several possible treatments were compared with usual care in patients
hospitalised with COVID-19. Eligible and consenting patients were randomly allocated (1: 1) …
[HTML][HTML] Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
O Abani, A Abbas, F Abbas, M Abbas, S Abbasi… - The Lancet, 2022 - thelancet.com
Background Casirivimab and imdevimab are non-competing monoclonal antibodies that
bind to two different sites on the receptor binding domain of the SARS-CoV-2 spike
glycoprotein, blocking viral entry into host cells. We aimed to evaluate the efficacy and safety
of casirivimab and imdevimab administered in combination in patients admitted to hospital
with COVID-19. Methods RECOVERY is a randomised, controlled, open-label platform trial
comparing several possible treatments with usual care in patients admitted to hospital with …
bind to two different sites on the receptor binding domain of the SARS-CoV-2 spike
glycoprotein, blocking viral entry into host cells. We aimed to evaluate the efficacy and safety
of casirivimab and imdevimab administered in combination in patients admitted to hospital
with COVID-19. Methods RECOVERY is a randomised, controlled, open-label platform trial
comparing several possible treatments with usual care in patients admitted to hospital with …